Coagulation and Fibrinolysis — MCQs
Von Willebrand disease involves a deficiency of which factor?
All are fibric acid derivatives except which of the following?
Which of the following statements regarding von Willebrand disease is incorrect?
Mechanism of action of tranexamic acid is
Following injury to a blood vessel, immediate hemostasis is achieved by:
Partial thromboplastin time (PTT) correlates with which pathway or function?
The clot formed after the coagulation cascade is not stable unless extensive cross-linking occurs. This is done by:
What is needed for prothrombin to thrombin conversion?
Which of the following drugs is a direct inhibitor of clotting factor Xa?
Cortisol increases all of the following components except:
Coagulation and Fibrinolysis Indian Medical PG Practice Questions and MCQs
Question 1: Von Willebrand disease involves a deficiency of which factor?
- A. Defect in platelet adhesion due to von Willebrand factor deficiency (Correct Answer)
- B. Defect in fibrin formation affecting clot stabilization
- C. Generalized defects involving small blood vessels
- D. Defect in clotting factors affecting secondary hemostasis
Explanation: ***Primary hemostasis*** - Von Willebrand disease primarily affects **primary hemostasis** due to defective or deficient **von Willebrand factor (vWF)**, which is crucial for platelet adhesion [1][3]. - This defect results in **increased bleeding tendencies**, exemplified by symptoms like easy bruising and prolonged bleeding from cuts [2]. *Secondary hemostasis* - Secondary hemostasis involves the **coagulation cascade**, not primarily affected in von Willebrand disease [3]. - Disorders related to secondary hemostasis typically involve factors like **factor VII, IX, or X**, unlike the vWF defect seen here [3]. *Generalized defects involving small vessels* - Generalized defects imply broader issues affecting the **microcirculation**, which is not the primary issue in von Willebrand disease. - While small vessel bleeding can occur, it is not specific to this condition as it does not primarily involve the **platelet aggregation** defect [1]. *Clot stabilization and resorption* - Clot stabilization and resorption primarily involve factors such as **fibrinogen** and cross-linking factors, rather than vWF. - Von Willebrand disease specifically impacts the **platelet function** and does not directly relate to stabilization processes once the clot has formed [1][3].
Question 2: All are fibric acid derivatives except which of the following?
- A. Clofibrate
- B. Gemfibrozil
- C. Fenofibrate
- D. Lovastatin (Correct Answer)
Explanation: ***Lovastatin***- **Lovastatin** is an example of a **statin drug**, which works by inhibiting **HMG-CoA reductase**, the rate-limiting enzyme in cholesterol synthesis, primarily lowering LDL cholesterol [1, 2].- Unlike fibric acid derivatives, statins do not primarily target **PPAR-alpha** receptors to reduce triglyceride levels.*Clofibrate*- **Clofibrate** is an older **fibric acid derivative** that primarily activates **PPAR-alpha** receptors, leading to decreased triglyceride production and increased lipoprotein lipase activity [1, 2].- It is one of the earliest drugs in this class, though now largely replaced by newer agents due to side effects.*Gemfibrozil*- **Gemfibrozil** is a commonly used **fibric acid derivative** that activates **PPAR-alpha**, resulting in a reduction of **triglycerides** and an increase in **HDL cholesterol** [1, 2].- It is effective in treating severe hypertriglyceridemia and mixed dyslipidemia.*Fenofibrate*- **Fenofibrate** is a **fibric acid derivative** that, like gemfibrozil, acts as a **PPAR-alpha agonist** to lower triglycerides and raise HDL cholesterol [1, 2].- It also has a beneficial effect on **uric acid levels** and can be used in patients with hyperuricemia.
Question 3: Which of the following statements regarding von Willebrand disease is incorrect?
- A. Type 2 von Willebrand disease is associated with a moderate bleeding tendency.
- B. Type 3 von Willebrand disease is associated with severe deficiency of factor VIII.
- C. Type 1 von Willebrand disease presents with severe bleeding since childhood. (Correct Answer)
- D. Type 2 von Willebrand disease includes subtypes with varying defects in von Willebrand factor.
Explanation: ***Type 1 von Willebrand disease presents with severe bleeding since childhood.*** - This statement is incorrect because **Type 1 von Willebrand disease (vWD)** is characterized by a **partial quantitative deficiency** of von Willebrand factor (vWF), leading to **mild to moderate bleeding** that typically presents later in life or with specific challenges like surgery. - **Severe bleeding since childhood** is more characteristic of **Type 3 vWD**, which involves a near-complete absence of vWF. *Type 2 von Willebrand disease is associated with a moderate bleeding tendency.* - This statement is correct as **Type 2 vWD** involves **qualitative defects** in vWF, meaning the protein is present but doesn't function correctly [1]. - This typically results in a **moderate bleeding tendency**, which can vary depending on the specific subtype (2A, 2B, 2M, 2N). *Type 3 von Willebrand disease is associated with severe deficiency of factor VIII.* - This statement is correct because **Type 3 vWD** is characterized by a near-complete absence of vWF, which is essential for stabilizing **Factor VIII** in circulation [2]. - The severe deficiency of vWF leads to a **marked decrease in Factor VIII levels**, resulting in a bleeding phenotype that can be difficult to distinguish from severe hemophilia A. *Type 2 von Willebrand disease includes subtypes with varying defects in von Willebrand factor.* - This statement is correct as **Type 2 vWD** is subdivided into four main types (2A, 2B, 2M, 2N), each with distinct **qualitative defects** in the von Willebrand factor protein [2]. - These subtypes are differentiated by issues such as **multimerization defects**, increased platelet binding, or decreased affinity for Factor VIII [2].
Question 4: Mechanism of action of tranexamic acid is
- A. Decrease vascular permeability
- B. Smooth muscle contraction
- C. Activates Plasmin formation
- D. Prevents fibrinolysis (Correct Answer)
Explanation: ***Correct: Prevents fibrinolysis*** - Tranexamic acid is an **antifibrinolytic agent** that works by inhibiting the activation of plasminogen to plasmin. - By preventing the formation of plasmin, it stabilizes **fibrin clots** and reduces bleeding. *Incorrect: Decrease vascular permeability* - This is primarily the mechanism of action of drugs like antihistamines or corticosteroids, which work on **inflammation** and **allergic reactions**. - Tranexamic acid does not directly target vascular permeability; its primary role is in **hemostasis**. *Incorrect: Smooth muscle contraction* - This describes the action of drugs like **vasoconstrictors** (e.g., epinephrine) or agents that promote uterine contractions (e.g., oxytocin). - Tranexamic acid has no direct effect on **smooth muscle contraction**. *Incorrect: Activates Plasmin formation* - This is the opposite of tranexamic acid's action; drugs that activate plasmin, such as **tissue plasminogen activators (tPAs)**, are used to break down clots. - Tranexamic acid specifically **inhibits plasminogen activation**, thereby preventing plasmin formation.
Question 5: Following injury to a blood vessel, immediate hemostasis is achieved by:
- A. Fibrin deposition
- B. Vasoconstriction (Correct Answer)
- C. Platelet adhesion
- D. Thrombosis
Explanation: ***Vasoconstriction*** - Following blood vessel injury, **vasoconstriction** occurs immediately, reducing blood flow and minimizing blood loss. - It is a **reflex response** mediated by local factors and neural mechanisms aiming to maintain hemostasis. *Fibrin deposition* - **Fibrin deposition** occurs later in the hemostatic process, primarily during the **coagulation phase** after initial vascular responses. - It is not an immediate response; rather, it's part of the **clot stabilization** process, requiring activation of the clotting cascade. *Thrombosis* - Thrombosis refers to the formation of a **blood clot** within a vessel, which happens after initial hemostatic mechanisms are activated. - It is not the **immediate** response post-injury; there is a sequence of events that lead to thrombosis after vasoconstriction and platelet activation. *Platelet adhesion* - Although platelet adhesion is crucial in hemostasis, it occurs following **vasoconstriction** and is not an immediate response to vessel injury [1][2]. - This process is part of the **primary hemostasis** phase, which cannot occur efficiently without prior initial vasoconstriction. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 581-582. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Hemodynamic Disorders, Thromboembolic Disease, and Shock, p. 128.
Question 6: Partial thromboplastin time (PTT) correlates with which pathway or function?
- A. Intrinsic pathway (Correct Answer)
- B. Extrinsic pathway
- C. Fibrinogen function
- D. Platelet function
Explanation: ***Function of platelets*** - The **partial thromboplastin time (PTT)** primarily assesses the **intrinsic and common pathways** of blood coagulation [1], indirectly reflecting platelet function through clotting factors. - Abnormal PTT can indicate issues with **platelet activation** and interactions in the clotting process, although it is not a direct measure of platelet count or function. *Intrinsic and common pathway* - While PTT is indeed related to the **intrinsic pathway** [1], it does not correlate directly with the **overall intrinsic pathway function** alone, as it primarily assesses clotting factor activity. - The **PTT** specifically examines factors like **factor VIII** and **IX** [1], rather than the broader aspect of the intrinsic mechanism itself. *Fibrinogen level* - Fibrinogen levels are assessed using the **prothrombin time (PT)** and not through PTT, as fibrinogen is involved in the **common pathway** but does not directly correlate with PTT. - Fibrinogen deficiency can affect clotting time, but the **PTT** primarily evaluates other factors independent of fibrinogen concentration. *Extrinsic and common pathway* - The **extrinsic pathway** is evaluated using **prothrombin time (PT)** [1], not PTT, which focuses on intrinsic factors' performance. - PTT measures factors involved mainly in the **intrinsic pathway**, including **factor XII**, **XI**, **IX**, and **VIII** [1], making this option incorrect. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Hemodynamic Disorders, Thromboembolic Disease, and Shock, pp. 128-130.
Question 7: The clot formed after the coagulation cascade is not stable unless extensive cross-linking occurs. This is done by:
- A. Plasmin
- B. Factor XIII (Correct Answer)
- C. Thrombin
- D. High molecular weight kininogen
Explanation: ***Factor XIII*** - **Factor XIIIa** (activated Factor XIII) is a **transglutaminase** that catalyzes the formation of **covalent bonds** between **fibrin monomers**, specifically between lysine and glutamine residues. - This cross-linking strengthens the **fibrin clot**, making it more resistant to mechanical stress and proteolytic degradation. *Plasmin* - **Plasmin** is an enzyme responsible for **fibrinolysis**, meaning it breaks down fibrin clots. - It acts to remodel and **dissolve clots**, not to stabilize them. *Thrombin* - **Thrombin** (Factor IIa) is a key enzyme in the coagulation cascade that converts **fibrinogen into fibrin monomers**. - While essential for clot formation, thrombin's primary role is to create the fibrin mesh, not to extensively cross-link it for stability. *High molecular weight kininogen* - **High molecular weight kininogen (HMWK)** is a cofactor in the **intrinsic coagulation pathway**, facilitating the activation of Factor XII and prekallikrein. - It is involved in initiating coagulation but does not directly participate in the cross-linking and stabilization of the fibrin clot.
Question 8: What is needed for prothrombin to thrombin conversion?
- A. Magnesium
- B. Sodium
- C. Calcium (Correct Answer)
- D. Potassium
Explanation: ***Calcium*** - **Calcium ions (Ca2+)** are absolutely essential cofactors for the conversion of **prothrombin to thrombin** in the coagulation cascade. - They are required for the formation and function of the **prothrombinase complex** (Factor Xa + Factor Va + Ca2+ + phospholipid surface). - Calcium binds to **γ-carboxyglutamic acid (Gla) residues** on prothrombin and Factor Xa, enabling them to anchor to phospholipid surfaces where the conversion occurs. - This is why **EDTA and citrate** (calcium chelators) are used as anticoagulants in blood collection tubes. *Magnesium* - **Magnesium** is an important cofactor for numerous enzymatic reactions (e.g., ATP-dependent enzymes, DNA/RNA polymerases). - However, it is **not directly involved** in the prothrombin to thrombin conversion step of the coagulation cascade. - Its primary roles are in DNA synthesis, muscle function, and nerve transmission. *Sodium* - **Sodium** is vital for maintaining fluid balance, osmotic pressure, nerve impulses, and muscle contractions. - It does **not play a direct role** as a cofactor in the prothrombinase complex or prothrombin to thrombin conversion. *Potassium* - **Potassium** is essential for maintaining cell membrane potential, nerve impulses, cardiac function, and muscle contraction. - It is **not a cofactor** for the enzymatic reactions involved in the coagulation cascade.
Question 9: Which of the following drugs is a direct inhibitor of clotting factor Xa?
- A. Argatroban
- B. Fondaparinux
- C. Apixaban (Correct Answer)
- D. Aspirin
Explanation: ***Apixaban*** - Apixaban is an **oral direct factor Xa inhibitor**, which means it directly binds to and inactivates factor Xa. - This inhibition prevents the conversion of **prothrombin to thrombin**, thereby disrupting the coagulation cascade. *Argatroban* - Argatroban is a **direct thrombin inhibitor** (DTI), meaning it selectively binds to and inhibits thrombin (factor IIa). - It is often used in cases of **heparin-induced thrombocytopenia (HIT)** due to its non-heparin-based mechanism of action. *Fondaparinux* - Fondaparinux is an **indirect factor Xa inhibitor** that binds to antithrombin, thereby enhancing antithrombin's ability to inactivate factor Xa. - It does not directly bind to factor Xa itself, but rather potentiates the action of a natural anticoagulant. *Aspirin* - Aspirin is an **antiplatelet agent** that inhibits cyclooxygenase (COX-1), thereby reducing the production of thromboxane A2. - This mechanism primarily inhibits **platelet aggregation** and adhesion, rather than directly inhibiting a clotting factor in the coagulation cascade.
Question 10: Cortisol increases all of the following components except:
- A. Monocytes
- B. RBCs
- C. Platelets
- D. Eosinophils (Correct Answer)
Explanation: ***Eosinophils*** - Cortisol causes **eosinopenia** (a decrease in eosinophils) by increasing their sequestration in tissues and promoting their apoptosis. - This effect is a classic indicator of stress and can be observed in conditions of elevated endogenous or exogenous cortisol. *Monocytes* - Cortisol typically causes a **mild monocytosis** (increase in circulating monocytes), although this effect can vary. - It impacts the trafficking and differentiation of monocytes, leading to their transient increase in the bloodstream. *RBCs* - Cortisol can lead to a slight **increase in red blood cell (RBC) count** or hemoglobin concentration. - This effect is partly due to hemoconcentration and partly by promoting erythropoiesis. *Platelets* - Cortisol generally causes a **thrombocytosis** (increase in platelet count). - This effect is thought to be mediated by various factors, including cytokine interactions and direct effects on megakaryopoiesis.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free